Key words: fish oil; hyperlipidaemia; renal transplantation; simvastatin Background. Recipients of renal transplantation (RT ) exhibit disturbances of serum lipids and apoproteins that may contribute to their cardiovascular morbidity and mortality. In our renal transplant department the
Introduction
hypercholesterolaemia prevalence at the first and fifth year of RT is 70.0% and 81.2%, respectively. LipidAtherosclerosis associated with hyperlipidaemia is a lowering therapy has been utilized in many Transplant major cause of morbidity and mortality after renal Units. The aim of our study was to evaluate post-RT transplantation (RT ) [1 ] . About 40% of deaths in RT hyperlipidaemia control with simvastatin or fish oil.
recipients are attributed to cardiovascular complicaMethods. Forty-three RT patients (26 men and 17
tions [2] . Intensive lipid-lowering therapy can reduce women) with persistent hypercholesterolaemia and the incidence of cardiovascular events by retarding the stable graft function which were resistant to a lipidprogression of coronary artery disease [3] . Chronic lowering diet (American Heart Association Step Two) rejection is the main cause of graft failure after the were randomized into two groups and treated for first year post-RT and the obstructive changes to the 3 months with simvastatin (S ) ( 10 mg/day; n=25)
arteries and arterioles represent a main feature of the and fish oil ( F) (6 g/day; n=18 ). Total cholesterol denominated 'graft atherosclerosis' [4]. ( TC ), LDL-cholesterol (LDL-C ), HDL-cholesterol Several approaches to the treatment of post-RT ( HDL-C ), lipoprotein a (Lp(a)), apolipoprotein A1 hyperlipidaemia have been advocated. b-hydroxy-b-( Apo A1), and apolipoprotein B ( Apo B) were monmethylglutaryl coenzyme A (HMG CoA) reductase itored and at the study baseline they were similar inhibitor therapy has been reported to improve lipid between the two groups.
abnormalities in RT patients [5 ] . Low-dose simvastatin Results. No side effects were detected after 3 months (10 mg/day) has been successfully used to improve of therapy. In group S, the concentrations of TC hyperlipidaemia in RT patients on cyclosporine [6 ] . ( 271±46 mg% vs 228±49 mg%; P<0.001), TG Fish oil, containing high concentrations of marine ( 180±78 vs 134±45; P<0.01), LDL-C (177±40 vs omega-3 polyunsaturated fatty acids such as eicosapen-144±43; P<0.01) and Apo B ( 96±18 vs 82±16; taenoic acid ( EPA, C2055v3) and docosahexaenoic P<0.001) were significantly reduced, and Apo A1 (DHA, C2256v3), are known to exert beneficial effects concentration had increased (135±24 vs 149±30; on serum lipid concentrations [7 ] and mortality from P<0.01). In group F, the concentrations of TC coronary artery disease or cerebrovascular accidents ( 266±25 vs 240±31; P<0.001), TG ( 203±105 vs [8] . It has also been associated with a reduced rate of 156±72; P=0.02) and HDL-C (63±15 vs 53±12; graft function deterioration in RT chronic rejection P<0.01) were significantly reduced. [9, 10] . Conclusions. We concluded that low-dose simvastatin
The objective of our study was to evaluate the and fish oil are both effective and safe in correcting efficacy of simvastatin and fish oil in post-RT hyperlipipost-RT hyperlipidaemia. Further prospective studies daemia treatment. with larger follow-up are needed to clarify whether this therapy has an impact on cardiovascular morbidity and mortality in RT patients. C=cholesterol, TG=triglycerides. Values are means±SD except for aIncluding enalapril (group S: 14, group F: 11), nifedipine (6-5), Lp(a), where medians and ranges are shown. All values are expressed diltiazem ( 0-1), minoxidil ( 0-1), amlodipine (1-0), atenolol (2-2), to the nearest ten. propranolol ( 1-1), metoprolol (0-1), metildopa (1-1 ), clonidine (1-0).
Azathioprine). The remainder were maintained with double cholesterol reduction diet with instruction (American Heart therapy (CsA+PRD). The CsA concentrations were measAssociation, Step Two) for 12 weeks. Thirteen patients were ured monthly during the study and did not differ between excluded for non-compliance.
the two groups. Thereafter, serum cholesterol of 43 RT patients ( 26 men Serum concentrations of TC, HDL-C, LDL-C, TG, Lp(a), and 17 women) remained elevated. These 43 RT patients Apo A1, and Apo B were determined in the early morning were randomized between groups S and F after their informed after a 12-14 h overnight fast. The serum was previously consent, and medicated for 3 months with: simvastatin separated and stored at 4°C. Standard enzymatic methods ( 10 mg/day; group S; n=25) or fish oil ( 6 g of fish oil were used to measure TC and TG (CHOD-PAP reagents; containing 30% EPA [C2055v3] and 20% DHA [C2256v3] Boehringer-MannheimB GmbH, Mannheim, Germany). and 0.5 mg of vitamin E per day; group F; n=18).
HDL-C was measured using the same reagents for the Patient details at study baseline including age, sex, time of phosphotungstic acid precipitation method. LDL-C was caldialysis, graft follow-up, creatinine, body mass index, total culated using the Friedewald formula [11] . Serum Lp(a) was prednisolone (PRD) dose, cyclosporine (CsA) dose, CsA measured by an enzymatic immunoradiometric assay. Apo concentration, 24-h urinary protein excretion, blood pressure, A1 and Apo B were measured by immunoturbidimetric antihypertensive treatment, and serum lipid profile, are given methods with commercially available standards and antisera in Tables 1 and 2 , and were similar between groups. No (Boehringer-MannheimB). At baseline, there were no signipatient was diabetic or received diuretic therapy and concom-ficant differences in lipids between groups S and F ( Table 2) . itant biliary or liver disease were excluded. The aetiologies Every two weeks the patients were examined and quesof renal failure were also similar between the groups. All the tioned about clinical adverse effects. Monthly haematological clinical variables remained relatively constant during the and biochemical profiles including serum creatinine, total study for both groups.
bilirubin, ALP, ALT, AST, and CPK were performed during The antihypertensive treatment generally consisted of enal-the study. Blood levels of simvastatin were not performed. april ( 14/17 for group S and 11/13 for group F ). Five Patients were informed of the possible side effects. patients of group S and six patients of group F received two Statistical analysis was performed by Student's paired t antihypertensive drugs. A triple antihypertensive treatment test. All data are reported as mean±SD, except for urinary was administered to two patients of both groups.
protein excretion and Lp(a) that were expressed in terms of b-Blockers were part of the antihypertensive treatment in median and range. Data analysis was performed using the three patients of group S and four patients of group F. All Mann-Whitney U test or the Student's t-test for comparison these patients were on double or triple antihypertensive of continuous variables with abnormal or normal population treatment (mean: 2.4±0.8 vs 1.4±0.5 antihypertensive drugs distributions, respectively. Differences were considered signiin the remaining patients; P<0.01), indicating that b-block-ficant at P<0.05. ers were used as a second-line drug. episodes. In addition, no adverse hepatic effects were even for RT recipients treated with CsA [6, 24] .
Martinez-Hernandez et al. using a lower dose of simvafound as the serum transaminases remained stable. Furthermore, CPK and serum creatinine values statin than used in this study ( 5 mg/day vs 10 mg/day) in a randomized single-blind placebo crossover study remained stable. The baseline mean CsA concentration (group S: 186±38 ng/ml, and group F: 189±30 ng/ml; [25] found that reductions in TC, LDL-C, and Apo B after 8 weeks of simvastatin therapy were significantly Pnot significant) was similar between the two groups and the mean body-weight remained stable throughout greater than with placebo. In our study it was remarkable that simvastatin significantly reduced the concenthe study (62.7 kg for group S and 64.3 kg for group F ). There were no variations in the haematological trations of TC, TG, LDL-C, and Apo B. It also reduced the ratio TC/HDL-C. profile in both groups during the study.
The values of TC, TG, LDL-C, HDL-C, Lp(a), Apo Dietary supplementation with fish oil is known to exert beneficial effects on serum lipid concentrations A1, and Apo B for the two groups, at the end of the study are showed in Table 2 .
[7] and on mortality from cardiovascular disease [8 ] .
Advantageous effects on renal reserve filtration capaAfter 3 months of low-dose simvastatin there were significant reductions in the TC (15.9%), TG ( 15.6%), city in CsA-treated RT recipients has been demonstrated [26 ] . LDL-C (18.6%) and Apo B (15.6%) concentrations. The Apo A1 concentration increased by 10.4%. There
In our study, fish oil was associated with a reduction of TC, HDL-C, and TG. The reduction of HDL-C were no significant changes in HDL-C and Lp(a) concentrations.
with consumption of fish oil is not detrimental, since it is related to an increase in HDL receptors and The group receiving fish oil registered significant reductions in TC (9.8%), TG (14.1%), and HDL-C accelerated turnover of HDL-C [27]. However, in nonhuman primates the prevention of atherosclerosis ( 16.9%) concentrations. The LDL-C, Lp(a), Apo A1, and Apo B concentrations remained stable.
by fish oil was associated with reductions in concentrations of HDL-C [28 ] . The TC/HDL-C ratio decreased significantly in group S (5.0±2.0 to 4.3±1.4; P=0.02) and slightly Serum concentrations of Lp(a) in humans are anywhere between 0 and >100 mg/dl. It is similar in increased in group F (4.4±1.0 to 4.6±0.9; P=0.38).
At the end of the study, the lipids values were not composition with LDL-C, but with a higher protein content and its physiological function is uncertain. Our significantly different between the two groups. Nevertheless the Apo B mean value tended to be lower observations agree with other studies, which reported reductions or no effect of HMG-CoA-reductase inhibin group S (group S: 82±16/group F: 92±16; P= 0.07).
itors on Lp(a) concentration [29, 30] . We conclude that low-dose simvastatin and fish oil (6 g/day) are effective in correcting hyperlipidaemia in
Discussion
RT recipients, even in lipid lowering diet resistant RT recipients. The lipid variations were strictly related with simvastatin or fish oil, as other variables which The post-RT lipid profile, especially if the patients receive CsA maintenance treatment, has been a subject could interfere, such as b-blockers, were maintained constant during the study. Our patients tolerated the of debate [12 ] . Several studies have showed a pattern of elevated concentrations of TC, LDL-C and treatment, without side effects, such as myopathy related to simvastatin or haemorrhagic episodes related VLDL-C1 [13 ] . HDL-C is usually normal or high, but there are occasional reports of low values [14, 15] . The to fish oil. The post-RT hyperlipidaemia treatment remains a subject of debate and future randomized prevalence of hyperlipidaemia post-RT ranges from 16% to 72% in the literature [13, 16 ] . In our renal controlled trials, with longer follow-up, are necessary to assess the value of lipid-lowering therapy in cardiotransplant department, the prevalence of hypercholesterolaemia in the first and fifth year post-RT is 70% vascular risk of these patients.
These results were presented at the XXXIIIrd and 81%, respectively.
Lovastatin, simvastatin, and fluvastatin therapy are Congress of the EDTA Congress (Amsterdam; Netherlands), June 1996. associated with serious side effects, such as rhabdomyolysis and acute renal failure, in heart or kidney transplant patients treated with CsA [17] [18] [19] .
However, low-dose HMG-CoA-reductase inhibitor can References be used in CsA-treated patients without significant risk 
